Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $6.63, but opened at $7.05. Valneva shares last traded at $6.89, with a volume of 1,702 shares trading hands.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim cut their price target on shares of Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, March 24th.
Read Our Latest Analysis on Valneva
Valneva Stock Up 4.0 %
The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The stock has a 50-day simple moving average of $6.93 and a 200-day simple moving average of $5.66. The firm has a market capitalization of $560.29 million, a PE ratio of -53.04 and a beta of 1.85.
Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The business had revenue of $56.48 million for the quarter, compared to analysts' expectations of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Analysts forecast that Valneva SE will post 0.13 EPS for the current year.
Hedge Funds Weigh In On Valneva
Several hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after buying an additional 30,859 shares in the last quarter. ABC Arbitrage SA purchased a new stake in Valneva in the 4th quarter worth approximately $84,000. Finally, GAMMA Investing LLC bought a new position in Valneva in the 1st quarter valued at $94,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
